By case
What's the case?
Your neurology resident and attending guide. Pick a scenario or browse all the tools.
Featured
Trending trials
Refreshes daily
NOR-TEST 2 (Part A)2022
Tenecteplase 0.4 mg/kg in moderate-severe stroke: sICH 6% vs 1% (6 versus 1 events, not statistically significant) and significantly higher mortality, 16% vs 5%.
ANNEXA-42019
Single-arm cohort: andexanet reduced anti-FXa by 92% with 82% hemostatic efficacy in FXa-inhibitor major bleeding.
ARAMIS2023
DAPT non-inferior to alteplase for minor nondisabling stroke at 90 d (93.8% vs 91.4%).
TASTE2024
Tenecteplase in perfusion-selected early-window stroke met per-protocol NI; ITT borderline.
DISTAL2025
EVT for medium/distal vessel occlusion did not improve outcome and trended toward harm.